XML 48 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Revenues (Tables)
12 Months Ended
Jan. 01, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Revenues consisted of the following (in thousands):
 Year Ended December 31,
 202020192018
Product revenues:
Gross product revenues$962,591 $957,621 $738,529 
Discounts and allowances(221,041)(197,671)(119,250)
Net product revenues741,550 759,950 619,279 
Collaboration revenues:
License revenues167,295 165,914 200,272 
Collaboration services revenues
78,693 41,911 34,275 
Total collaboration revenues245,988 207,825 234,547 
Total revenues$987,538 $967,775 $853,826 
Net product revenues by product were as follows (in thousands):
Year Ended December 31,
202020192018
CABOMETYX
$718,687 $733,421 $599,946 
COMETRIQ
22,863 26,529 19,333 
Net product revenues
$741,550 $759,950 $619,279 
Schedule of Concentration Risks As of December 31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
 
December 31,
 
20202019
Collaboration partners
Ipsen23 %38 %
Takeda10 %%
Product revenue customers
Affiliates of McKesson Corporation12 %14 %
Affiliates of CVS Health Corporation 11 %10 %
Affiliates of AmerisourceBergen Corporation11 %11 %
Affiliates of Optum Specialty Pharmacy%10 %
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
 
Year Ended December 31,
 
202020192018
Ipsen15 %16 %21 %
Affiliates of CVS Health Corporation14 %15 %13 %
Affiliates of McKesson Corporation12 %12 %12 %
Affiliates of Optum Specialty Pharmacy11 %13 %14 %
Affiliates of AmerisourceBergen Corporation11 %11 %%
Revenues Disaggregated by Geographic Region
Total revenues by geographic region were as follows (in thousands):
Year Ended December 31,
202020192018
U.S.
$752,890 $770,244 $632,927 
Europe
151,631 152,771 182,879 
Japan
83,017 44,760 38,020 
Total revenues
$987,538 $967,775 $853,826 
Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances
The activities and ending allowance balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
Chargebacks, Discounts for Prompt Payment and Other
Other Customer Credits/Fees and Co-pay Assistance
Rebates
Total
Balance at December 31, 2018
$2,322 $3,038 $11,916 $17,276 
Provision related to sales made in:
Current period129,936 15,605 48,250 193,791 
Prior periods3,989 (111)3,880 
Payments and customer credits issued(128,733)(15,035)(44,946)(188,714)
Balance at December 31, 2019
7,514 3,497 15,222 26,233 
Provision related to sales made in:
Current period146,537 16,162 58,049 220,748 
Prior periods33 (352)612 293 
Payments and customer credits issued(144,231)(16,028)(56,479)(216,738)
Balance at December 31, 2020
$9,853 $3,279 $17,404 $30,536 
Schedule of Other Assets and Other Liabilities Contract assets and liabilities were as follows (in thousands):
 
December 31,
 
20202019
Contract assets(1)
$— $1,062 
Contract liabilities:
Current portion(2)
$1,790 $— 
Long-term portion(3)
3,755 6,596 
Total contract liabilities$5,545 $6,596 
____________________
(1)    Presented in prepaid expenses and other current assets in the accompanying Consolidated Balance Sheets.
(2)    Presented in other current liabilities in the accompanying Consolidated Balance Sheets.
(3)    Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.